THERMO FISHER SCIENTIFIC

(TMO)
  Report
Real-time Estimate Cboe BZX  -  02:34 2022-08-12 pm EDT
600.14 USD   +1.28%
10:19aThermo Fisher Scientific Quote on India's 75 years of independence
AQ
08:15aTHERMO FISHER SCIENTIFIC : FDA Approves First NGS Based Companion Diagnostic to Aid in Selecting Non Small Cell Lung Cancer Patients with HER2 ERBB2 Activating Mutations SNVs Exon 20 Insertions for Treatment with ENHERTU
PU
08/08Thermo Fisher Scientific Launches Enhanced Applied Biosystems HIV-1 Genotyping Kit
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific Inc. Updates Applied Biosystems QuantStudio 5 Dx Real-Time PCR System to Comply with IVDR Regulations

06/07/2022 | 08:00am EDT

Thermo Fisher Scientific is offering an IVDR version of the Applied Biosystems QuantStudio 5 Dx Real-Time PCR System globally. The innovative qPCR system simplifies molecular diagnostic workflows for infectious disease and oncology. Molecular diagnostic kit manufacturers and clinical testing labs that develop their own assays need open qPCR platforms that meet IVDR requirements. The IVDR-compliant QuantStudio 5 Dx System will enable molecular diagnostic manufacturers to develop new IVDR-compliant tests under the new regulations. The system will also help clinical labs running diagnostic tests switch to IVDR qPCR testing. Among the system's updates, the multi-mode software is now IVDR compliant, providing dual functionality for running diagnostic tests and developing new assays in today's regulatory environment. The qPCR system comes with an intuitive touchscreen and simplified, efficient workflow that minimizes steps to deliver quality results in as little as 30 minutes. In addition, a security, auditing, e-signature module provides secure operation. The updated QuantStudio 5 Dx Real-Time PCR System is available in all regions that recognize CE-IVD certification and is also listed with the U.S. Food and Drug Administration (FDA).


© S&P Capital IQ 2022
All news about THERMO FISHER SCIENTIFIC
10:19aThermo Fisher Scientific Quote on India's 75 years of independence
AQ
08:15aTHERMO FISHER SCIENTIFIC : FDA Approves First NGS Based Companion Diagnostic to Aid in Sel..
PU
08/08Thermo Fisher Scientific Launches Enhanced Applied Biosystems HIV-1 Genotyping Kit
CI
08/05THERMO FISHER SCIENTIFIC INC. Management's Discussion and Analysis of Financial Condit..
AQ
08/04Thermo Fisher Scientific Introduces Highly Sensitive Research Assays for Measurable Res..
CI
08/04THERMO FISHER SCIENTIFIC : Expands Cell Culture Media Manufacturing Site in Grand Island N..
PU
08/03INSIDER SELL : Thermo Fisher Scientific
MT
08/03Thermo Fisher Scientific and Structura Biotechnology Collaborate to Offer a Solution fo..
BU
08/03Thermo Fisher Scientific Inc. and Structura Biotechnology Inc. Collaborate to Offer Sol..
CI
08/01Thermo Fisher Scientific Inc. Unveils Thermo Scientific Arctis Cryo-Plasma Focused Ion ..
CI
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 43 124 M - -
Net income 2022 6 884 M - -
Net Debt 2022 24 684 M - -
P/E ratio 2022 34,1x
Yield 2022 0,20%
Capitalization 232 B 232 B -
EV / Sales 2022 5,96x
EV / Sales 2023 5,72x
Nbr of Employees 130 000
Free-Float 88,7%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 592,54 $
Average target price 661,45 $
Spread / Average Target 11,6%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
THERMO FISHER SCIENTIFIC-11.20%232 151
DANAHER CORPORATION-11.50%211 818
INTUITIVE SURGICAL, INC.-34.31%84 285
EDWARDS LIFESCIENCES CORPORATION-19.78%64 424
SIEMENS HEALTHINEERS AG-20.63%60 400
BOSTON SCIENTIFIC CORPORATION-1.69%59 784